
简介:
- 作者: Xiaobo Wang, Mary P. Moore, Hongxue Shi, Yang Xiao, Jiayu Zhang, Lanuza A. P. Faccioli, Zhiping Hu, Shareef Khalid, Danish Saleheen, Dwayne G. Stupack, Tatiana Kisseleva, Alejandro Soto Gutierrez, Mitchell A. Lazar & Ira Tabas
- 杂志: Nature Metabolism
- Doi: https://www.doi.org/10.1038/s42255-025-01355-1
- 出版日期: 2025/9/26
摘要
Metabolic-dysfunction-associated steatohepatitis (MASH) is the leading cause of chronic liver disease, but an incomplete understanding of MASH-induced liver fibrosis has limited therapeutic options. Here we show that hepatocyte caspase-8 drives MASH fibrosis through an apoptosis-independent mechanism. Hepatic caspase-8 expression correlates with liver fibrosis in both human and experimental MASH, and hepatocyte-specific caspase-8 deletion in male mice with MASH suppressed liver fibrosis and hepatic stellate cell (HSC) activation without affecting hepatocyte apoptosis. Mechanistic studies showed that a caspase-8–YY1 pathway in hepatocytes induces secretory meteorin (Metrn), which activates HSCs via a c-Kit–STAT3 pathway. Meteorin expression was increased in human and male mouse MASH livers and decreased by deletion of hepatocyte caspase-8 in MASH mice and human and mouse primary hepatocytes. Genetic restoration of hepatocyte meteorin in hepatocyte-caspase-8-deleted MASH mice restored HSC activation and liver fibrosis while silencing hepatocyte meteorin lowered liver fibrosis. These findings reveal a therapeutically targetable pathway promoting MASH fibrosis involving a non-apoptotic function of caspase-8 and a newly discovered HSC activator, meteorin.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
